CIPO Patents = 4

EPO Patents = 6

Forward Citations = 101

Loading Chart...

3 inventors (with patents filed for the assignee):

Makoto Koizumi (4 out of 49 patents)

Masafumi Matsuo (4 out of 14 patents)

Yasuhiro Takeshima (4 out of 6 patents)

4. Masafumi Matsuo (0 patent)

4 patents: Sort by Forward Citations

1. 9657050 - ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors (2017-05-23),

2. 9657049 - ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors (2017-05-23),

3. 9243026 - ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors (2016-01-26),

4. 8624019 - ENA nucleic acid drugs modifying splicing in mRNA precursor (2014-01-07),

Orphan Disease Treatment Institute Co., Ltd. is a leading biopharmaceutical company dedicated to developing innovative treatments for rare and orphan diseases. With a focus on research and development, we aim to bring hope to patients suffering from these neglected diseases. Our team of experts is committed to making a difference in the lives of those affected by orphan diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

4 Patents

#2,780 in Tokyo

#7,416 in Japan

Tokyo, Japan

Orphan Disease Treatment Institute Co., Ltd.

Forward Citations = 101

3 inventors:

Makoto Koizumi (4 out of 49 patents)

Masafumi Matsuo (4 out of 14 patents)

Yasuhiro Takeshima (4 out of 6 patents)

4. Masafumi Matsuo (0 patent)

Please report any incorrect information to support@idiyas.com

4 patents (CIPO):

Please report any incorrect information to support@idiyas.com

6 patents (EPO):

Please report any incorrect information to support@idiyas.com